Clinical Trials Logo

Clinical Trial Summary

Recent evidence suggests that curcumin supplementation may reduce muscle inflammation, oxidative markers, and muscle damage. The most favourable dosage to elicit these ergogenic effects are yet to be established; both 750mg & 1500mg has been shown to be effective. Curcumin supplementation has been ingested in numerous different ways however, no previous research to date has used curcumin in a hydrolysed (drinkable) format. The aim of this study is to investigate whether hydrolysed curcumin can reduce indices of muscle damage and improve recovery, whilst also examining a potential dose-response effect.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05346211
Study type Interventional
Source St Mary's University College
Contact Luke Hughes, PhD
Phone +447920004214
Email luke4.hughes@northumbria.ac.uk
Status Not yet recruiting
Phase N/A
Start date May 1, 2022
Completion date September 30, 2023

See also
  Status Clinical Trial Phase
Completed NCT04458662 - Iron and Muscular Damage: FEmale Metabolism and Menstrual Cycle During Exercise
Completed NCT01845558 - Effects of Wobenzym® Plus in Healthy, Sportive People After Eccentric Exercise Phase 4
Completed NCT04273789 - Effect of Far Infrared Reflecting Sleepwear on Recovery and Sleep N/A
Completed NCT03284450 - Exercise Induced Muscle Damage Post Dance and Sprint Specific Exercise in Females N/A